4Giaccone G.Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer[J].J Clin Oncol,2005,23(14):3235-3242.
5Maione P,Rossi A,Airoma G,et al.The role of targeted therapy in non-small cell lung cancer[J].Crit Rev Oncol Hematol,2004,51(1):29-44.
6Lynch TJ,Bell DW,Sordella R.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2004,350(21):2129-2139.
7Tsao MS,Sakurada A,Cutz JC.Erlotinib in lung cancermolecular and clinical predictors of outcome[J].N Engl J Med,2005,353(2):133-144.
8Kobayashi S,Boggon TJ,Dayaram T.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2005,352(8):786-792.
9Thatcher N,Chang A,Parikh P,et al.Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer:results from a randomised placebo-controlled,multicentre study (lressa Survival Evaluation in Lung Cancer[J].Lancet,2005,366(9496):1527-1537.
6Pao W,Miller VA,Politi KA,et al.Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain[J].PLoS Med,2005,2(3):e73.
7Yun CH,Mengwasser KE,Toms AV,et al.The T790M mutation in EGFR kinase causes drug resistance by in-creasing the affinity for ATP[J].Proc Natl Acad Sci USA,2008,105(6):2070-2075.
8Kosaka T,Yatabe Y,Endoh H,et al.Mutations of the epi-dermal growth factor receptor gene in lung cancer:biolog-ical and clinical implications[J].Cancer Res,2004,64(24):8919-8923.
9Pao W,Wang TY,Reily GJ,et al.KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib and erloitinib[J].PLoS Med,2005,2(1):e17.
10Learn CA,Hartzell TL,Wikstrand CJ,et al.Resistance to tyrosine kinase inhibition by mutant epidermal growth fac-tor receptor variantⅢcontributes to the neoplastic phe-notype of glioblastoma multiforme[J].Clin Cancer Res,2004,10(9):3216-3224.
